MBIO News and Press, Mustang Bio Inc. From 03/18/19

Mustang Bio (NASDAQ: MBIO ): FY GAAP EPS of -$1.14. More news on: Mustang Bio, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...

NEW YORK, March 18, 2019 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumo...

NEW YORK, March 13, 2019 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a company focused on the development of novel immunotherapies based on proprietary chimeric antigen receptor engineered T cell (CAR T) technology and gene therapies for rare diseases, to...

Mustang Bio ( MBIO -1.2% ) will collaborate with Nationwide Children's Hospital on the development of an oncolytic (cancer killing) virus (C134) for the treatment of glioblastoma multiforme, the most common type of brain tumor. More news on: Mustang Bio, Inc., Healthcare stocks ne...

Phase 1 trial underway at the University of Alabama at Birmingham in recurrent glioblastoma multiforme Mustang intends to combine the oncolytic virus (C134) with MB-101 (IL13Rα2-specific CAR) to potentially enhance efficacy in treating glioblastoma multiforme NEW YORK and CO...

In (yet another) statement , FDA Commission Scott Gottlieb, M.D. announces the issuance of final updated guidance for gene therapy and cell therapy developers. More news on: Abeona Therapeutics Inc., Bellicum Pharmaceuticals, ZIOPHARM Oncology, Inc., Healthcare stocks news, Read more ...

Gainers:  SPI Energy (NASDAQ: SPI ) +45% . SilverSun Technologies (NASDAQ: SSNT ) +30% . Proteostasis Therapeutics (NASDAQ: PTI ) +26% . Enochian Biosciences ( OTCQB:ENOB ) +20% . Nemaura Medical (NASDAQ: NMRD ) +19% . Select Interior Concepts (NASDAQ: SIC ) +18% . Replimune Gro...

A Long Road Ahead Mustang Bio ( MBIO ) has fallen over 70% the last 52 weeks as the company continues to struggle to push through their pipeline of immunotherapies . Progress will need to accelerate if the company wants to survive as MBIO has sky high product potential, but does not cur...

Bellicum Pharmaceuticals ( BLCM ) like many small-cap biopharmaceutical companies have experienced a share price devaluation over 2018. The company has yet to truly recover from the clinical hold the FDA placed on the BPX-501 following three cases of encephalopathy deemed as possibly related...